Graduate School at Shenzhen, Tsinghua University, Shenzhen, People's Republic of China. Open FIESTA Center, Tsinghua University, Shenzhen 518055, People's Republic of China. Department of Mechanical Engineering and Mechanics, Tsinghua University, Beijing, People's Republic of China.
Biofabrication. 2018 Feb 20;10(2):025010. doi: 10.1088/1758-5090/aaa97e.
The liver is one of the main metabolic organs, and nearly all ingested drugs will be metabolized by the liver. Only a small fraction of drugs are able to come onto the market during drug development, and hepatic toxicity is a major cause for drug failure. Since drug development is costly in both time and materials, an in vitro liver model that can accelerate bioreactions in the liver and reduce drug consumption is imperative in the pharmaceutical industry. The liver on a chip is an ideal alternative for its controllable environment and tiny size, which means constructing a more biomimetic model, reducing material consumption as well as promoting drug diffusion and reaction. In this study, taking advantage of the laminar flow on chips and using natural degradable gel rat tail Collagen-I, we constructed a liver sinusoid on a chip. By synchronously injecting two kinds of cell-laden collagen, HepG2-laden collagen and HUVEC-laden collagen, we formed two collagen layers with a clear borderline. By controlling the HUVEC density and injection of growth factors, HUVECs in collagen formed a monolayer through self-assembly. Thus, a liver sinusoid on a chip was achieved in a more biomimetic environment with a more controllable and uniform distribution of discrete HUVECs. Viability, album secretion and urea synthesis of the live sinusoid on a chip were analysed on days 3, 5 and 7 after collagen injection with acetaminophen treatment at 0 (control), 10 and 20 mM. The results indicated that our liver sinusoid on a chip was able to maintain bioactivity and function for at least 7 d and was beneficial for hepatotoxic drug screening.
肝脏是主要的代谢器官之一,几乎所有摄入的药物都会在肝脏中代谢。只有一小部分药物在药物开发过程中能够上市,而肝毒性是药物失败的主要原因。由于药物开发在时间和材料方面都非常昂贵,因此在制药行业中,需要一种能够加速肝脏生物反应并减少药物消耗的体外肝脏模型。由于其可控的环境和微小的尺寸,芯片上的肝脏是一种理想的替代品,这意味着构建更仿生的模型,减少材料消耗,促进药物扩散和反应。在本研究中,利用芯片上的层流并使用天然可降解凝胶鼠尾胶原蛋白 I,我们构建了芯片上的肝窦。通过同步注射两种细胞包被的胶原,即 HepG2 包被的胶原和 HUVEC 包被的胶原,我们形成了两层胶原,边界清晰。通过控制 HUVEC 的密度和生长因子的注射,胶原中的 HUVEC 通过自组装形成单层。因此,在更仿生的环境中,通过更可控和均匀的离散 HUVEC 分布,实现了芯片上的肝窦。在用对乙酰氨基酚(0(对照)、10 和 20mM)处理后,在胶原注射后的第 3、5 和 7 天,分析了芯片上的肝窦的活力、白蛋白分泌和尿素合成。结果表明,我们的芯片上的肝窦至少能够维持 7 天的生物活性和功能,并且有利于肝毒性药物筛选。